Eledon Pharmaceuticals, Inc.
ELDN
$1.59
$0.117.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.99% | -1.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -22.90% | 37.68% | |||
| Operating Income | 22.90% | -37.68% | |||
| Income Before Tax | -55.66% | -72.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -55.66% | -72.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -55.66% | -72.69% | |||
| EBIT | 22.90% | -37.68% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -55.36% | -72.68% | |||
| Normalized Basic EPS | -55.34% | -72.81% | |||
| EPS Diluted | -55.36% | -72.68% | |||
| Normalized Diluted EPS | -55.34% | -72.81% | |||
| Average Basic Shares Outstanding | 0.15% | 0.04% | |||
| Average Diluted Shares Outstanding | 0.15% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||